DK1272188T3 - Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer - Google Patents

Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer

Info

Publication number
DK1272188T3
DK1272188T3 DK00973002T DK00973002T DK1272188T3 DK 1272188 T3 DK1272188 T3 DK 1272188T3 DK 00973002 T DK00973002 T DK 00973002T DK 00973002 T DK00973002 T DK 00973002T DK 1272188 T3 DK1272188 T3 DK 1272188T3
Authority
DK
Denmark
Prior art keywords
breast cancer
tyrosine kinase
treatment
egfr tyrosine
kinase inhibitors
Prior art date
Application number
DK00973002T
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of DK1272188T3 publication Critical patent/DK1272188T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00973002T 1999-11-02 2000-11-01 Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer DK1272188T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (1)

Publication Number Publication Date
DK1272188T3 true DK1272188T3 (da) 2007-01-29

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00973002T DK1272188T3 (da) 1999-11-02 2000-11-01 Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer

Country Status (21)

Country Link
US (1) US7553815B1 (da)
EP (1) EP1272188B1 (da)
JP (1) JP2003513035A (da)
KR (1) KR100785359B1 (da)
CN (1) CN1197577C (da)
AT (1) ATE339957T1 (da)
AU (1) AU779190B2 (da)
BR (1) BR0015194A (da)
CA (1) CA2389411C (da)
CY (1) CY1106285T1 (da)
DE (1) DE60030889T2 (da)
DK (1) DK1272188T3 (da)
ES (1) ES2275556T3 (da)
GB (1) GB9925958D0 (da)
IL (1) IL149176A0 (da)
MX (1) MXPA02004272A (da)
NO (1) NO323206B1 (da)
NZ (1) NZ518696A (da)
PT (1) PT1272188E (da)
WO (1) WO2001032155A2 (da)
ZA (1) ZA200203431B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101135233B1 (ko) 2000-05-19 2012-04-12 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1441736A2 (en) * 2001-10-29 2004-08-04 Novartis AG Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
BR0311814A (pt) * 2002-06-05 2005-03-15 Cedars Sinai Medical Center Método de tratar câncer empregando inibidores de cinase
US20070059785A1 (en) * 2003-08-15 2007-03-15 Smithkline Beecham Corporation Biomarkers in cancer
DE602004004553T2 (de) 2003-09-19 2007-10-25 Astrazeneca Ab Chinazolinderivate
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
TWI441646B (zh) 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
ES2440481T3 (es) 2005-02-23 2014-01-29 Genentech, Inc. Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2011009498A (es) 2009-03-11 2011-10-14 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos.
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
WO1996030347A1 (en) * 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
DK0836605T3 (da) * 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
CN1314917A (zh) * 1998-05-15 2001-09-26 伊姆克罗尼系统公司 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤
EP2059902B1 (en) 2006-08-28 2010-04-07 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
DE60030889T2 (de) 2007-04-05
AU1155901A (en) 2001-05-14
GB9925958D0 (en) 1999-12-29
JP2003513035A (ja) 2003-04-08
US7553815B1 (en) 2009-06-30
PT1272188E (pt) 2007-01-31
ES2275556T3 (es) 2007-06-16
IL149176A0 (en) 2002-11-10
CA2389411A1 (en) 2001-05-10
KR100785359B1 (ko) 2007-12-18
WO2001032155A3 (en) 2002-05-10
ZA200203431B (en) 2003-02-26
MXPA02004272A (es) 2003-08-20
NO20022065L (no) 2002-06-24
KR20020064306A (ko) 2002-08-07
CN1197577C (zh) 2005-04-20
NO20022065D0 (no) 2002-04-30
AU779190B2 (en) 2005-01-13
EP1272188B1 (en) 2006-09-20
CA2389411C (en) 2009-09-01
EP1272188A2 (en) 2003-01-08
NO323206B1 (no) 2007-01-22
DE60030889D1 (de) 2006-11-02
CN1387437A (zh) 2002-12-25
BR0015194A (pt) 2002-06-18
NZ518696A (en) 2004-12-24
CY1106285T1 (el) 2011-10-12
WO2001032155A2 (en) 2001-05-10
ATE339957T1 (de) 2006-10-15

Similar Documents

Publication Publication Date Title
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
DK1255537T3 (da) Farnesylproteintransferasehæmmere til behandling af brystcancer
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MY169308A (en) Treatment of tnf? related disorders
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
TNSN04015A1 (en) Combination therapy for the treatment of cancer
SE0300098D0 (sv) Use of cyclin D1 inhibitors
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
GB0121494D0 (en) Compounds
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
GEP201606538B (en) Preoperative treatment of post operative pain
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
NO20024545D0 (no) Fremgangsmåte for behandling av kongestiv hjertefeil
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей